Lupus & antiphospholipid syndrome
CAR T-cell therapy in SLE: A systematic review
Authors' conclusion
This systematic review evaluated all the available clinical evidence on the use of CAR T-cell therapy in patients with SLE. The findings reinforce the efficacy of this treatment modality
Study context
- Population
- Patients with SLE treated with CAR therapy in clinical studies (MEDLINE, Embase, Scopus, CENTRAL)
- Participants
- 145 patients16 studies
- Outcome
- SLEDAI (pooled, 102 individual scores)
Methodological detailsPRISMA, pooled analysis
- PRISMA
- Pooled analysis
Pooled result
As reported in the abstract
Mean baseline SLEDAI
13.1
95% CI 12.3–13.9
SLEDAI after 6 months
2.3
95% CI 1.5–3.1
SLEDAI after 12 months
1.4
95% CI 0.3–2.4
Further pooled results
DORIS remission
- DORIS remission achieved
- 45/64 patients (70%)
LLDAS
- LLDAS achieved
- 50/56 (89%)
Safety
CRS
- CRS occurred
- 81 (56%)
- Grade 1 or 2
- 80 (98%)
- Grade 3
- 1 (2%)
ICANS
- ICANS reported
- 4
- Grade 2
- 1
- Grade 3
- 1
- Grade 4
- 1
- Grade 1
Serious infections
- Serious infections
- 11 (7.6%)
- Fatal pneumococcal meningitis
- 1
Original publication
CAR T-cell therapy in SLE: A systematic review. Semin Arthritis Rheum. Published 16 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →